Skip to main content

Abdel. G Elkahloun, Ph. D.

Associate Investigator, Cancer Genetics and Comparative Genomics Branch
Head, Microarray Core facility

Scientific Summary

As a technology provider, the microarray core is involved in a wide range of projects looking at the characterizing of either the global expression profiles or genes sets to use as framework for diagnostics, drugs treatment and/or assays to further define the disease in question.

Most recently, Dr. Elkahloun scientific interest switched to defining exosomes or EVs (extra-cellular vesicles) in cancer. In 2014, and in collaboration with Dr. Roberts at NCI, Dr. Elkahloun demonstrated that exosomes derived from cancer cells can affect the transcriptomes of surrounding cells, specifically vascular endothelial cells through microRNAs and noncodingRNAs. Current research is aiming at defining in details the molecular mechanism behind the regulated sorting of specific RNA species in specific exosomes.

During the course of several collaborations with investigator from NIMH (National Institute of Mental Health); Dr. Kleinman (first temporal global gene expression across the human life span in normal and schizophrenic patients), Dr. Chuang (Bipolar disease) and Dr. Saavedra (Alzheimer's disease), Dr. Elkahloun gained experience the genetics of neurodegenerative and neuropsychiatric diseases. In 2015, in a cross comparative and integrative analysis of global gene expression profile, Dr. Elkahloun was able to show that Candesartan, an FDA approved drug used to treat hypertension, is in fact neuroprotective and could be used for early preventive treatment in Alzheimer's disease.

Posted: December 13, 2016